Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age12+
SponsorUniversity of Alaska Fairbanks

About this trial

The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Self-identify as a permanent resident of the study community

Be a youth between the ages of 12-17 years or an adult 18+

Be able to provide written informed consent

Disqualifiers

Does not have permanent residence in the community or has lived in the community less than 5 years

Is unable to provide written informed consent

Trial design

Design model

Single group

Treatments tested in this trial

  • Tools for Arctic Health Promotion

    Behavioral

    The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023). A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.

Treatment groups

360 Participants
are divided into 1 treatment group
Group A: Enrollment in TAHPExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation

The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives. We will analyze how individual stress indicators are mitigated over time by intervention participation.

Time frame
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
2

General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation

The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction. We will assess how the intervention mitigates life satisfaction with individuals who participate.

Time frame
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
3

We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire

The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks. We will assess how the intervention impacts depressive symptoms with individual participation.

Time frame
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
4

We will assess if anxiety symptoms decrease with intervention participation using the GAD-7

The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants

Time frame
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

Secondary outcomes

1

We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale

The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth. This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement. We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.

Time frame
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

Other outcomes

1

We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.

To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response. These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time. Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day. Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.

Time frame
Day 1 (baseline), 8 months (T2) and at 20 months (T3)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: